Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918548 | 0.90 | JAK2 (0.36) | ALDH1A1KMT2ASMN1; SMN2NPSR1JAK2 | |
| SCHEMBL9921771 | 0.80 | KDM4E (0.39) | ALDH1A1SMN1; SMN2JAK1JAK3HPGD | |
| SCHEMBL9918554 | 0.80 | PDE3B (0.40) | JAK2JAK1HTR1ASLC6A4JAK3 | |
| SCHEMBL9918552 | 0.79 | HTT (0.39) | ALDH1A1KMT2AJAK2JAK1JAK3 | |
| SCHEMBL9918550 | 0.79 | PRKCA (0.30) | — | |
| SCHEMBL9918551 | 0.72 | MAP3K11 (0.35) | KMT2AJAK2JAK1TYK2JAK3 | |
| SCHEMBL9921664 | 0.70 | MAP3K11 (0.41) | ALDH1A1KMT2AJAK2JAK1TYK2 | |
| SCHEMBL9918533 | 0.69 | MAP3K11 (0.41) | ALDH1A1SMN1; SMN2JAK2JAK1TYK2 | |
| SCHEMBL9921770 | 0.68 | SMN1; SMN2 (0.42) | ALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL9918547 | 0.67 | JAK2 (0.32) | ALDH1A1KMT2ASMN1; SMN2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 1507/4885KMT2A 628/4885SMN1; SMN2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.